Hanx Biopharmaceuticals

Hanx Biopharmaceuticals is a China-rooted, globally oriented clinical-stage biopharmaceutical company focused on innovative antibody therapeutics for cancer and autoimmune diseases. The company has built internal capabilities spanning antibody discovery, structural biology, translational medicine, clinical development, CMC industrialization, and international registration. Its pipeline is centered on immuno-oncology, ADCs, and autoimmune programs, with lead assets including HX009 in Phase 2 development and additional clinical candidates such as HX301 and HX044. Hanx highlights two proprietary platforms, VersatiBody for multifunctional antibodies and autoRx40 for autoimmune therapeutics, which support development of first-in-class and best-in-class candidates. The company listed in Hong Kong in late 2025 and operates across China plus selected international development locations including the United States and Australia.